This week on Mind Meets Machine: Global, I sat down with Nilou Hashimi, whose path into neuroengineering started with an 11-hour emergency brain surgery.

We covered a lot of ground:

→ How a decade of medical uncertainty, from a facial paralysis to a life-altering surgery, shaped Nilou's decision to pursue rehabilitation engineering and neuroscience

→ A parallel reflection on navigating health uncertainty and what it does to your sense of time and control

→ The unglamorous realities of running pediatric neuroscience studies: recruitment, attention spans, and getting clean signal from young, disabled participants

→ Where AI is already changing the pace of EEG and signal processing research, and where the field is still catching up

→ Whether we're close to predicting anxiety or panic states before they escalate, and why individual variability makes this harder than it sounds

→ The emerging (and still niche) world of space neuroscience, and what microgravity might teach us about the nervous system

This week: the gap between reading a brain signal and understanding what it means.

I spoke with Atif Mahmood, a computational neuroscience researcher building real time EEG neurofeedback tools for children's emotional regulation, about the hard problems in translating brain data into usable insight.

We cover:
→ Why brain activity readings can be misleading without context
→ How gaming architecture solved real time neurofeedback delivery
→ Mindful, an EEG tool helping children self regulate
→ The rigor gap between engineering and science
→ A closing thought experiment on privacy versus collective safety

A sharp look at what it takes to build trustworthy neurotech.

While GLP-1 drugs and established medtech pulled in billions and shrugged off tariffs, early-stage biotech funding hit a five-year low and neurotech startups were left fighting for scraps.

→ Political leverage is now a balance sheet asset. Novo Nordisk and Eli Lilly negotiated directly with the White House and walked away with three years of tariff relief. That's not luck. That's strategic positioning translating straight into capital insulation.

→ The companies best placed to benefit from reshoring incentives are the least likely to need them. Large pharma has the balance sheet to onshore and negotiate. The startups actually driving the next wave of innovation, especially in BCI and neurotech, have none of those levers.

→ Uncertainty is more expensive than bad news. The moment the MFN deal structure became visible, capital that had been sitting on the sidelines moved fast. Leaders who resolved ambiguity early outperformed the ones who waited for clarity to arrive on its own.

→ BCI is now a patient capital game. No revenue, no reimbursement, no seat at the negotiating table. The investors still in this space are underwriting a 7 to 10 year horizon, not a quarter.

If you're leading, regulating, or investing anywhere near biotech or neurotech, the through-line is the same: the market is rewarding decisive adaptation, not wait-and-see.

REFERENCES:

[1] FDA API sourcing data, via DelveInsight (Sep 2025).[2] Grassi Advisors (Jun 2025).[3] DCAT Value Chain Insights (Apr 2025).[4] DCAT Value Chain Insights (Jul 2025).[5] Pharmaceutical Technology (Apr 2026) — source for BIO CEO John Crowley quote and pharma reshoring commitments.[6] Pharmaceutical Technology (Apr 2026) — 16 MFN companies incl. Pfizer, Eli Lilly, MSD.[7] White House Presidential Proclamation, Adjusting Imports of Pharmaceuticals (Apr 2026).[8] White House Proclamation [7]; Pharmaceutical Technology [5] — generics/biosimilars exemption.[9] ING analyst Diederik Stadig, via Pharmaceutical Technology [5].[10] Morrison Foerster, BIOSECURE Act Update (Dec 2025).[11] Baker McKenzie, The BIOSECURE Act Becomes Law (Jan 2026).[12] Latham & Watkins, BIOSECURE Act Becomes Law.[13] DelveInsight [1] — 4-in-10 generics/Chinese APIs; reshoring announcements.[14] BIO member survey (Mar 2025), via DCAT VCI [4] and HubXchange (Apr 2025).[15] DelveInsight [1] — 25% Canada/Mexico device tariffs.[16] Janus Henderson Investors, Why Healthcare Stocks Could Excel in 2026 (Dec 2025).[17] EY, Pulse of the MedTech Report 2025 (Sep/Oct 2025).[18] Granted AI, FY2026 Science Budget Scorecard (Feb 2026); FABBS, FY26 Budget Request (Jun 2025) for proposed-cut context.[19] MDC Associates, NIH Budget Cuts and Realignment (2025).[20] Andersen Lab, BCIs in 2025: Trials, Progress, and Challenges (Jul 2025).[21] Fortune Business Insights, Brain Computer Interface Market.[22] Prime Therapeutics, GLP-1 Pipeline Update (Nov 2025).[23] IQVIA, Outlook for Obesity in 2026 (Jan 2026).[24] EY, Pulse of the MedTech Report 2025 [17].[25] BioPharma Dive / HSBC Innovation Banking (Jul 2025).[26] Ropes & Gray LLP, From Volatility to Vitality (Mar 2026).[27] Janus Henderson Investors [16].[28] William Blair, The Quarterly Rx: Q2 2025 Recap (Jul 2025).[29] Pharmaceutical Technology, Biotech Recovery in Q3 2025 (Oct 2025).[30] PitchBook Q2 2025 MedTech VC Trends, via HTD Health (Jan 2026).[31] IQVIA [23].[32] Labiotech.eu, Six Key Obesity Deals of 2025 (Dec 2025).[33] IQVIA [23].[34] J.P. Morgan, Weight Loss Drug Supply and Demand in 2026 (Feb 2026).[35] Paradromics, Healthtech and the FDA (Nov 2025).